CVE:AQS

Aequus Pharmaceuticals Competitors

C$0.20
-0.01 (-4.76 %)
(As of 04/20/2021 09:37 AM ET)
Add
Compare
Today's Range
C$0.19
Now: C$0.20
C$0.20
50-Day Range
C$0.19
MA: C$0.22
C$0.28
52-Week Range
C$0.07
Now: C$0.20
C$0.29
Volume62,100 shs
Average Volume683,599 shs
Market CapitalizationC$26.19 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Aequus Pharmaceuticals (CVE:AQS) Vs. HVT, EVE, SUGR, NU, LBL, and THCX

Should you be buying AQS stock or one of its competitors? Companies in the industry of "drug manufacturers - specialty & generic" are considered alternatives and competitors to Aequus Pharmaceuticals, including Harvest One Cannabis (HVT), Eve & Co Incorporated (EVE), SugarBud Craft Growers (SUGR), NeutriSci International (NU), Lattice Biologics (LBL), and (THCX.V) (THCX).

Aequus Pharmaceuticals (CVE:AQS) and Harvest One Cannabis (CVE:HVT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation.

Analyst Recommendations

This is a summary of current recommendations and price targets for Aequus Pharmaceuticals and Harvest One Cannabis, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aequus Pharmaceuticals0000N/A
Harvest One Cannabis0000N/A

Valuation & Earnings

This table compares Aequus Pharmaceuticals and Harvest One Cannabis' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aequus PharmaceuticalsC$2.28 million11.50C$-2,880,394.00C($0.02)-9.09
Harvest One CannabisC$8.50 million3.42C$-89,908,156.00C($0.36)-0.32

Aequus Pharmaceuticals has higher earnings, but lower revenue than Harvest One Cannabis. Aequus Pharmaceuticals is trading at a lower price-to-earnings ratio than Harvest One Cannabis, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Aequus Pharmaceuticals and Harvest One Cannabis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aequus PharmaceuticalsN/AN/AN/A
Harvest One CannabisN/AN/AN/A

Summary

Aequus Pharmaceuticals beats Harvest One Cannabis on 3 of the 5 factors compared between the two stocks.

Aequus Pharmaceuticals (CVE:AQS) and Eve & Co Incorporated (CVE:EVE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation.

Analyst Recommendations

This is a summary of current recommendations and price targets for Aequus Pharmaceuticals and Eve & Co Incorporated, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aequus Pharmaceuticals0000N/A
Eve & Co Incorporated0000N/A

Valuation & Earnings

This table compares Aequus Pharmaceuticals and Eve & Co Incorporated's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aequus PharmaceuticalsC$2.28 million11.50C$-2,880,394.00C($0.02)-9.09
Eve & Co IncorporatedC$2.84 million3.35C$-9,154,266.00C($0.32)-1.04

Aequus Pharmaceuticals has higher earnings, but lower revenue than Eve & Co Incorporated. Aequus Pharmaceuticals is trading at a lower price-to-earnings ratio than Eve & Co Incorporated, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Aequus Pharmaceuticals and Eve & Co Incorporated's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aequus PharmaceuticalsN/AN/AN/A
Eve & Co IncorporatedN/AN/AN/A

Summary

Aequus Pharmaceuticals beats Eve & Co Incorporated on 3 of the 5 factors compared between the two stocks.

Aequus Pharmaceuticals (CVE:AQS) and SugarBud Craft Growers (CVE:SUGR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation.

Analyst Recommendations

This is a summary of current recommendations and price targets for Aequus Pharmaceuticals and SugarBud Craft Growers, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aequus Pharmaceuticals0000N/A
SugarBud Craft Growers0000N/A

Valuation & Earnings

This table compares Aequus Pharmaceuticals and SugarBud Craft Growers' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aequus PharmaceuticalsC$2.28 million11.50C$-2,880,394.00C($0.02)-9.09
SugarBud Craft GrowersC$66,906.00402.61C$-962,178,924.00C($1.79)-0.03

Aequus Pharmaceuticals has higher revenue and earnings than SugarBud Craft Growers. Aequus Pharmaceuticals is trading at a lower price-to-earnings ratio than SugarBud Craft Growers, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Aequus Pharmaceuticals and SugarBud Craft Growers' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aequus PharmaceuticalsN/AN/AN/A
SugarBud Craft GrowersN/AN/AN/A

Summary

Aequus Pharmaceuticals beats SugarBud Craft Growers on 3 of the 5 factors compared between the two stocks.

Aequus Pharmaceuticals (CVE:AQS) and NeutriSci International (CVE:NU) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation.

Analyst Recommendations

This is a summary of current recommendations and price targets for Aequus Pharmaceuticals and NeutriSci International, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aequus Pharmaceuticals0000N/A
NeutriSci International0000N/A

Valuation & Earnings

This table compares Aequus Pharmaceuticals and NeutriSci International's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aequus PharmaceuticalsC$2.28 million11.50C$-2,880,394.00C($0.02)-9.09
NeutriSci InternationalC$69,626.00416.05C$-1,982,032.00C($0.01)-14.62

NeutriSci International has lower revenue, but higher earnings than Aequus Pharmaceuticals. NeutriSci International is trading at a lower price-to-earnings ratio than Aequus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Aequus Pharmaceuticals and NeutriSci International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aequus PharmaceuticalsN/AN/AN/A
NeutriSci InternationalN/AN/AN/A

Summary

NeutriSci International beats Aequus Pharmaceuticals on 3 of the 5 factors compared between the two stocks.

Aequus Pharmaceuticals (CVE:AQS) and Lattice Biologics (CVE:LBL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation.

Profitability

This table compares Aequus Pharmaceuticals and Lattice Biologics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aequus PharmaceuticalsN/AN/AN/A
Lattice BiologicsN/AN/AN/A

Analyst Recommendations

This is a summary of current recommendations and price targets for Aequus Pharmaceuticals and Lattice Biologics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aequus Pharmaceuticals0000N/A
Lattice Biologics0000N/A

Valuation & Earnings

This table compares Aequus Pharmaceuticals and Lattice Biologics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aequus PharmaceuticalsC$2.28 million11.50C$-2,880,394.00C($0.02)-9.09
Lattice BiologicsC$2.24 million2.58C$-2,436,142.00C($0.02)-2.37

Lattice Biologics has lower revenue, but higher earnings than Aequus Pharmaceuticals. Aequus Pharmaceuticals is trading at a lower price-to-earnings ratio than Lattice Biologics, indicating that it is currently the more affordable of the two stocks.

Summary

Lattice Biologics beats Aequus Pharmaceuticals on 3 of the 5 factors compared between the two stocks.

Aequus Pharmaceuticals (CVE:AQS) and (THCX.V) (CVE:THCX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.

Profitability

This table compares Aequus Pharmaceuticals and (THCX.V)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aequus PharmaceuticalsN/AN/AN/A
(THCX.V)N/AN/AN/A

Analyst Ratings

This is a summary of current ratings and target prices for Aequus Pharmaceuticals and (THCX.V), as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aequus Pharmaceuticals0000N/A
(THCX.V)0000N/A

Valuation and Earnings

This table compares Aequus Pharmaceuticals and (THCX.V)'s revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aequus PharmaceuticalsC$2.28 million11.50C$-2,880,394.00C($0.02)-9.09
(THCX.V)N/AN/AN/AN/AN/A

(THCX.V) has lower revenue, but higher earnings than Aequus Pharmaceuticals.

Summary

Aequus Pharmaceuticals beats (THCX.V) on 1 of the 1 factors compared between the two stocks.


Aequus Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Harvest One Cannabis logo
HVT
Harvest One Cannabis
0.4$0.12-4.3%C$21.51 millionC$8.50 million-0.32Gap Down
EVE
Eve & Co Incorporated
1.0$0.33-1.5%C$21.32 millionC$2.84 million-1.04Gap Down
SUGR
SugarBud Craft Growers
0.7$0.05-0.0%C$11.81 millionC$66,906.00-0.03Gap Down
NU
NeutriSci International
0.5$0.19-2.6%C$8.65 millionC$69,626.00-14.62
LBL
Lattice Biologics
0.5$0.05-0.0%C$4.67 millionC$2.24 million-2.37
THCX
(THCX.V)
0.6$5.30-6.2%C$0.00N/A0.00High Trading Volume
GLH
31444
0.4N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
ACG
438280
0.6N/AN/AC$0.00N/A0.00Gap Down
HC
815446
0.5N/AN/A$0.00N/A0.00Gap Down
BIO
Bio-Rad Laboratories
0.5N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
BBM
Blueberries Medical
0.6N/AN/A$0.00N/A0.00High Trading Volume
LOVE
Cannara Biotech
0.7N/AN/A$0.00N/A0.00High Trading Volume
CALI
China Auto Logistics
1.3N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
MJ
ETFMG Alternative Harvest ETF
0.5N/AN/A$0.00N/A0.00News Coverage
Gap Down
BOSS
Global X Founder-Run Companies ETF
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
LHS
Liberty Health Sciences
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
LIB
Liberty Leaf
0.5N/AN/AC$0.00N/A0.00High Trading Volume
Gap Down
MMEN
Medmen Enterprises
0.6N/AN/A$0.00N/A0.00High Trading Volume
RQB
Ravenquest Biomed
0.6N/AN/A$0.00N/A0.00High Trading Volume
TGIF
SoFi Weekly Income ETF
0.6N/AN/A$0.00N/A0.00High Trading Volume
Valeant Pharmaceuticals International logo
VRX
Valeant Pharmaceuticals International
0.5N/AN/AC$0.00N/A0.00
VRT
Vertiv
0.5N/AN/A$0.00N/A0.00Gap Down
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.